Holen Sie sich die Stockscreener-App
285.50
0.64%
2.47
Schlusskurs vom Vortag:
$283.03
Offen:
$283.81
24-Stunden-Volumen:
34,776
Relative Volume:
0.13
Marktkapitalisierung:
$31.62B
Einnahmen:
$5.36B
Nettoeinkommen (Verlust:
$287.73M
KGV:
113.16
EPS:
2.5229
Netto-Cashflow:
$924.18M
1W Leistung:
+3.69%
1M Leistung:
-10.14%
6M Leistung:
-16.39%
1J Leistung:
+6.53%
1-Tages-Spanne:
$281.13
$286.01
1-Wochen-Bereich:
$271.47
$289.76
52-Wochen-Spanne:
$196.45
$385.22
Beone Medicines Ltd Adr Stock (ONC) Company Profile
Firmenname
Beone Medicines Ltd Adr
Sektor
Branche
Telefon
41-616851900
Adresse
C/O BEONE MEDICINES I GMBH, BASEL
Compare ONC vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ONC
Beone Medicines Ltd Adr
|
284.86 | 31.42B | 5.36B | 287.73M | 924.18M | 2.5229 |
VRTX
Vertex Pharmaceuticals Inc
|
439.96 | 110.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.95 | 77.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
702.94 | 42.91B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.56 | 42.09B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
153.03 | 31.32B | 606.42M | -1.28B | -997.58M | -6.403 |
Beone Medicines Ltd Adr Stock (ONC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Eingeleitet | Wolfe Research | Outperform |
| 2026-03-16 | Herabstufung | Jefferies | Buy → Hold |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-09-18 | Eingeleitet | Barclays | Overweight |
| 2025-04-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-03-03 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-12-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2024-09-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-02-06 | Fortgesetzt | JP Morgan | Overweight |
| 2023-09-12 | Eingeleitet | Macquarie | Outperform |
| 2023-08-17 | Eingeleitet | Jefferies | Buy |
| 2023-07-17 | Eingeleitet | Citigroup | Buy |
| 2023-06-30 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-01-12 | Eingeleitet | Daiwa Securities | Buy |
| 2022-10-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-10-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-08-09 | Fortgesetzt | JP Morgan | Overweight |
| 2022-03-17 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-02-07 | Eingeleitet | Deutsche Bank | Buy |
| 2021-10-12 | Eingeleitet | Bernstein | Outperform |
| 2021-10-06 | Hochstufung | CLSA | Underperform → Buy |
| 2021-03-08 | Eingeleitet | China Renaissance | Buy |
| 2021-03-01 | Herabstufung | CLSA | Outperform → Underperform |
| 2020-11-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-06 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-11-06 | Herabstufung | Piper Sandler | Neutral → Underweight |
Alle ansehen
Beone Medicines Ltd Adr Aktie (ONC) Neueste Nachrichten
BeOne Medicines (NASDAQ:ONC) Shares Gap Up – Here’s Why - Defense World
JPMorgan Chase & Co. Sells 47,002 Shares of BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors - GlobeNewswire Inc.
BeOne Medicines Ltd.Sponsored ADR $ONC Shares Bought by AIA Group Ltd - MarketBeat
Brokerages Set BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) PT at $401.00 - Defense World
Jain Global LLC Sells 32,244 Shares of BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Chan Henry Lee Sells 341 Shares of BeOne Medicines (NASDAQ:ONC) Stock - MarketBeat
Capital International Investors Boosts Stake in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Capital International Sarl Has $50.61 Million Stake in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Capital Group Private Client Services Inc. Reduces Stock Holdings in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Pinpoint Asset Management Singapore Pte. Ltd. Has $1.49 Million Stock Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BeOne Medicines (ONC) Is Down 15.1% After Surging To GAAP Profitability And Raising 2026 GuidanceHas The Bull Case Changed? - Sahm
JPMorgan Chase & Co. Has $16.63 Million Stock Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
TD Asset Management Inc Takes $9.33 Million Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BeOne Medicines (NASDAQ:ONC) Price Target Raised to $410.00 - Defense World
BeOne Medicines (ONC) Reports $1.5B Revenue for Q4, $1.1B from Lymphoma Treatment - Finviz
Artisan Partners Limited Partnership Reduces Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Artisan Partners Limited Partnership Reduces Position in BeOne Medicines Ltd. – Sponsored ADR $ONC - Defense World
Generali Investments Management Co LLC Takes Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BeOne Medicines (NASDAQ:ONC) Shares Gap Down After Earnings Miss - Defense World
Here's What Important Indicators Reveal About BeOne Medicines Ltd.Sponsored ADR (ONC) Fourth Quarter Results - Bitget
Here's What Key Metrics Tell Us About BeOne Medicines Ltd.Sponsored ADR (ONC) Q4 Earnings - Yahoo Finance
BEONE MEDICINES LTD-ADR (NASDAQ:ONC) Passes Minervini's SEPA Screen with Strong Technicals and High Growth Momentum - ChartMill
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
M&G PLC Has $41.17 Million Holdings in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
ABN Amro Investment Solutions Lowers Holdings in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
ABN Amro Investment Solutions Lowers Holdings in BeOne Medicines Ltd. – Sponsored ADR $ONC - Defense World
Bernstein Remains a Buy on BeOne Medicines AG (ONC) - Finviz
Candriam S.C.A. Sells 67,718 Shares of BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Chan Henry Lee Sells 1,660 Shares of BeOne Medicines (NASDAQ:ONC) Stock - MarketBeat
BeOne Medicines Trial Wins And Sonrotoclax Clearance Meet Valuation Discount - Sahm
3 Stocks to Buy in February - Finviz
Wall Street Bullish on BeOne Medicines AG (ONC) amid Robust Pipeline Development - Finviz
Mirae Asset Global Investments Co. Ltd. Acquires 38,992 Shares of BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Citizens Highlights BeOne Medicines' (ONC) $3.8B Revenue Potential for 2025 - Finviz
BeOne Medicines Collaboration Extends Safety Modeling As Shares Trade Below Targets - Sahm
Assessing BeOne Medicines (ONC) Valuation After Expanded InSysBio Collaboration On Clinical Trial Modeling - Sahm
Did BeOne’s New Uptrend And Upgraded Earnings Outlook Just Shift Its (ONC) Investment Narrative? - simplywall.st
EMCOR Group, Inc. (NYSE:EME) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Financial Review: Atossa Genetics (NASDAQ:ATOS) versus ADM Tronics Unlimited (OTCMKTS:ADMT) - Defense World
BeOne Medicines (NASDAQ:ONC) Shares Gap DownShould You Sell? - MarketBeat
BeOne Medicines Earnings Momentum Spurs Valuation Debate And Analyst Optimism - Sahm
Finanzdaten der Beone Medicines Ltd Adr-Aktie (ONC)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.19%
0.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):